Table 1.
Clinical characteristics of subjects
| Variables | |
|---|---|
| Number of patients | 146 |
| Mini-mental state examination score | 27.8 ± 3.1 |
| Male, n (%) | 111 (76.0%) |
| Age, y | 70.9 ± 8.6 |
| Body mass index, kg/m2 | 23.5 ± 3.4 |
| Systolic blood pressure, mmHg | 127 ± 16.3 |
| Diastolic blood pressure, mmHg | 71 ± 11.6 |
| Low-density lipoprotein cholesterol, mg/dL | 96.0 ± 34.4 |
| Triglycerides, mg/dL | 124.5 ± 70.3 |
| High-density lipoprotein cholesterol, mg/dL | 55.0 ± 14.7 |
| HbA1c, % | 6.7 ± 5.5 |
| Fasting plasma blood glucose, mg/dL | 130.0 ± 58.7 |
| Brain natriuretic peptide, pg/mL | 151.6 ± 274.2 |
| Left ventricular ejection fraction, % | 58.6 ± 11.2 |
| Fatty acids | |
| Docosahexaenoic acid, μg/mL | 132.5 ± 52.2 |
| Eicosapentaenoic acid, μg/mL | 68.9 ± 40.4 |
| Arachidonic acid, μg/mL | 173.0 ± 43.4 |
| Dihomogammalinolenic acid, μg/mL | 34.5 ± 11.4 |
| Complications | |
| Dyslipidemia, n (%) | 126 (86.3%) |
| Hypertension, n (%) | 131 (89.7%) |
| Diabetes mellitus, n (%) | 80 (54.8%) |
| Cerebrovascular disease, n (%) | 25 (17.1%) |
| Smoking, n (%) | 108 (74.0%) |
| Drugs | |
| ACEI/ARB, n (%) | 91 (62.3%) |
| β-blockers, n (%) | 53 (36.3%) |
| Calcium channel blockers, n (%) | 62 (42.5%) |
| Statins, n (%) | 123 (84.2%) |
| Ezetimibe, n (%) | 8 (5.5%) |
| Diuretics loop, n (%) | 27 (18.5%) |
| Mineralocorticoid antagonists, n (%) | 7 (4.8%) |
Unless indicated otherwise, data are presented as the mean ± standard deviation.
ACEI, angiotensin converting enzyme inhibitors; ARB, angiotensin II receptor blockers.